The newly issued patents cover (US) methods of isolating molecules from cells by exposing the cells to elevated pressures, such as at least 500 psi; to isolating biological components from a sample; and to inactivating proteins by hydrostatic pressure; (Japan) methods and apparatus in which pressure provides precise control over the timing and synchronization of chemical - particularly enzymatic – reactions; (Canada and Australia); sterilization, decontamination, or disinfection by repeated cycling between high and low pressures, and (Australia) multiple chamber sample processing devices for use in the automated and sequential homogenization, processing, detection, and analysis of biological samples in a pressure-modulation apparatus.

Updated Research Report (Dated December 1, 2009)
Updated Earnings Note (Dated November 16, 2009)
Updated Research Report (Dated September 1, 2009)
Updated Earnings Note (Dated August 13, 2009)
Updated Research Report (Dated June 16, 2009)
Updated Earnings Note (Dated May 12, 2009)
Updated Research Report (Dated April 28, 2009)
Updated Research Report (Dated April 2, 2009)
Updated Earnings Note (Dated November 17, 2008)
Updated Research Report (Dated August 28, 2008)
Updated Earnings Note (Dated August 15, 2008)
Updated Research Report (Dated November 29, 2007)
Updated Earnings Note (Dated November 12, 2007)
Updated Research Report (Dated September 7, 2007)
Updated Research Report (Dated June 19, 2007)
Updated Research Report (Dated April 13, 2007)
Initial Research Report (Dated January 8, 2007)

*The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. As of the date of this report, we, our affiliates, any officer, director or stockholder, or any member of their families do not have a position in the stock of the Company mentioned in this report. All research issued by Taglich Brothers, Inc. is based on public information. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned in this report and was not a manager or co-manager of any offering for the company with in the last three years. In October, 2006, the company paid a monetary engagement fee of $19,500 (USD) for the first year of creation and dissemination of research reports and will pay a monthly monetary fee of $1,750 (USD) to Taglich Brothers, Inc. for the creation and dissemination of research reports. For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.